These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34854413)

  • 21. Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs.
    Roilides E; Antachopoulos C; Simitsopoulou M
    Mycoses; 2014 Dec; 57 Suppl 3():40-7. PubMed ID: 25175306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection.
    Wang H; Yuan Y; Xiao M; Chen L; Zhao Y; Haiwei Zhang ; Long P; Zhou Y; Xu X; Lei Y; Bihao Wu ; Diao T; Cai H; Liu L; Shao Z; Wang J; Bai Y; Wang K; Peng M; Liu L; Han S; Mei F; Cai K; Lei Y; Pan A; Wang C; Gong R; Li X; Wu T
    Cell Mol Immunol; 2021 Jul; 18(7):1832-1834. PubMed ID: 34099890
    [No Abstract]   [Full Text] [Related]  

  • 23. Herpes zoster as a potential complication of coronavirus disease 2019.
    Pona A; Jiwani RA; Afriyie F; Labbe J; Cook PP; Mao Y
    Dermatol Ther; 2020 Nov; 33(6):e13930. PubMed ID: 32602610
    [No Abstract]   [Full Text] [Related]  

  • 24. [Iron and invasive fungal infection].
    Álvarez F; Fernández-Ruiz M; Aguado JM
    Rev Iberoam Micol; 2013; 30(4):217-25. PubMed ID: 23684655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.
    Sharma S; Grover M; Bhargava S; Samdani S; Kataria T
    J Laryngol Otol; 2021 May; 135(5):442-447. PubMed ID: 33827722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism.
    Petraitis V; Petraitiene R; Antachopoulos C; Hughes JE; Cotton MP; Kasai M; Harrington S; Gamaletsou MN; Bacher JD; Kontoyiannis DP; Roilides E; Walsh TJ
    Med Mycol; 2013 Jan; 51(1):72-82. PubMed ID: 22686246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
    Ibrahim AS; Spellberg B; Edwards J
    Curr Opin Infect Dis; 2008 Dec; 21(6):620-5. PubMed ID: 18978530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis.
    Gebremariam T; Alkhazraji S; Soliman SSM; Gu Y; Jeon HH; Zhang L; French SW; Stevens DA; Edwards JE; Filler SG; Uppuluri P; Ibrahim AS
    Sci Adv; 2019 Jun; 5(6):eaaw1327. PubMed ID: 31206021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights.
    VasanthiDharmalingam P; Karuppagounder V; Watanabe K; Karmouty-Quintana H; Palaniyandi SS; Guha A; Thandavarayan RA
    Drug Discov Today; 2021 May; 26(5):1265-1274. PubMed ID: 33493677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Has SARS-CoV-2 reached peak fitness?
    Burioni R; Topol EJ
    Nat Med; 2021 Aug; 27(8):1323-1324. PubMed ID: 34155413
    [No Abstract]   [Full Text] [Related]  

  • 31. Host defenses against zygomycetes.
    Roilides E; Kontoyiannis DP; Walsh TJ
    Clin Infect Dis; 2012 Feb; 54 Suppl 1():S61-6. PubMed ID: 22247447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Does reduced interferon immunity lead to more serious COVID-10 symptoms?].
    Gudbjartsson D
    Laeknabladid; 2020 Nov; 106(11):501. PubMed ID: 33107839
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients.
    Millon L; Larosa F; Lepiller Q; Legrand F; Rocchi S; Daguindau E; Scherer E; Bellanger AP; Leroy J; Grenouillet F
    Clin Infect Dis; 2013 May; 56(10):e95-101. PubMed ID: 23420816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
    Bouayad A
    Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.
    Schulze B; Rambach G; Schwartze VU; Voigt K; Schubert K; Speth C; Jacobsen ID
    Virulence; 2017 Nov; 8(8):1657-1667. PubMed ID: 28750194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2-specific virulence factors in COVID-19.
    Kumar A; Prasoon P; Kumari C; Pareek V; Faiq MA; Narayan RK; Kulandhasamy M; Kant K
    J Med Virol; 2021 Mar; 93(3):1343-1350. PubMed ID: 33085084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19).
    Karimi-Galougahi M; Arastou S; Haseli S
    Int Forum Allergy Rhinol; 2021 Jun; 11(6):1029-1030. PubMed ID: 33713565
    [No Abstract]   [Full Text] [Related]  

  • 38. Invasive mucormycosis in a renal transplant recipient.
    Allam SR; Madhrira MM; Memon IA; Tessier J; Johnson JA; Dao A; Rofaiel G
    Kidney Int; 2020 Jan; 97(1):216. PubMed ID: 31901346
    [No Abstract]   [Full Text] [Related]  

  • 39. Black Fungus Complicated with COVID-19 in a Man with Underlying Non-Hodgkin's Lymphoma.
    Nelwan EJ; Tunjungputri RN; Wardani RS; Wahyuningsih R
    Acta Med Indones; 2021 Jul; 53(3):349-351. PubMed ID: 34611076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucormycosis in COVID-19 recovered patients.
    Kumar A
    J Med Virol; 2022 Apr; 94(4):1272-1273. PubMed ID: 34905224
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.